The 13th International Conference on Drug-Drug Interactions (DDI) was held in Seattle, WA this past week. The conference was a focused symposium examining the current scientific concepts and practices in DDI evaluation. Topics covered included inhibition and induction of drug metabolizing enzymes, especially Cytochrome P450s, and drug efflux and uptake transporter enzymes. The conference had approximately 120 attendees spanning academia, government regulatory agencies (FDA), the pharmaceutical industry, and tool providers.
A pre-conference workshop was held, which included a session concentrating on “Higher-Throughput Evaluation of DDI”. During this session a talk was given by BioTek accentuating the project work that has been done to demonstrate the utility of our instruments to be used for automated multiplexed cell-based Cytochrome P450 assays. While not all of the industry may be ready to move into a higher throughput format, many attendees seemed interested in the type of instrumentation that BioTek had to offer for these types of applications.
The remainder of the conference focused on why DDI studies are performed, and the enzymes that play a role in drug absorption, distribution, metabolism, and excretion (ADME), that when inhibited or induced can lead to potential adverse drug-drug interactions. The goal was to move towards determining the best techniques for examining the ADME of new chemical entities (NCE), as well as how these potential new drugs may affect the efficacy of other co-administered drugs. It was clear, by the end of the conference, that even though the number of adverse drug-drug interactions being reported in the literature is decreasing, there is still much work that needs to be done to increase the confidence in the results that are being published, as well as being placed on the labels of prescriptions in your medicine cabinet.
By, BioTek Instruments